Viral Conjunctivitis Treatment Study
common.study.values.description
“Viral Conjunctivitis Treatment Study”
The objective of this study is to determine the efficacy AvenovaAR (0.01% hypochlorous acid) in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated with AvenovaAR will have a quicker resolution of their ocular signs and symptoms of Viral Conjunctivitis compared with artificial tears.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-no
Device - 0.01% Hypochlorous acid
Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
Placebo
Placebo to be used four times a day to the affected eye for 2 weeks
participant.views.study.view.additional
participant.views.study.view.scientific-title
Avenova for the Treatment of Viral Conjunctivitis
common.study.values.clinical-trial-id
NCT03861728
participant.views.study.view.id
e73M8e
